<DOC>
	<DOC>NCT01230177</DOC>
	<brief_summary>This survey is conducted to investigate safety and efficacy under the post marketed drug utilization on the patient with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy) at the time of switching regimen from 10 mg twice a week administration to 25 mg once a week administration.</brief_summary>
	<brief_title>Etanercept (Enbrel) Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>Implemented as a Special Investigation by Central Registration System</detailed_description>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patients need to be administered etanercept in order to be enrolled in the survey Patients who have changed regimen from 10 mg twice a week administration to 25 mg once a week administration. Patients who have been administered etanercept 50mg once a week Patients who have been administered etanercept 25mg once a week</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>